Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report

Table 3 Four cases of autoimmune hepatitis development following direct antiviral agent treatment

Ref.	Age	Sex	HLA-DR4	Autoimmune disease	Genotype	DAA	Onset	Treatment	Follow up
Matsumoto et al[29], 2018	81	Female	Negative	None	1 (serotype)	EBR/GZR	2 months	PSL	Improvement
Covini et al[31], 2018	72	Female	NA	ITP	1b	SOF/LDV	2 wk	PSL	Improvement
Montón et al[30], 2020	72	Female	NA	None	1b	SOF/LDV	3 yr	PSL	Improvement
Our case	80	Female	Positive	None	1b	SOF/LDV	9 months	PSL + UDCA	Development of PSC

DAA: Direct antiviral agent; EBR/GZR: Elbasvir/Grazoprevir; HLA: Human leukocyte antigen; ITP: Idiopathic thrombocytopenic purpura; PSC: Primary sclerosing cholangitis; PSL: Prednisolone; SOF/LDV: Sofosbuvir/Ledipasvir; UDCA: Ursodeoxycholic acid.